Mallinckrodt Drug Patent Portfolio
Mallinckrodt owns 6 orange book drugs protected by 71 US patents with Acthar Gel having the least patent protection, holding only 1 patent. And Inomax with maximum patent protection, holding 44 patents. Given below is the list of Mallinckrodt's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11752199 | Methods of modulating pericytes | 18 Jul, 2041 | Active |
| US10335452 | Method of treating patients with hepatorenal syndrome type 1 | 05 Apr, 2037 | Active |
| US9770570 | Apparatus and method for monitoring nitric oxide delivery | 03 Nov, 2036 | Active |
| US9770570 | Apparatus and method for monitoring nitric oxide delivery | 03 May, 2036 | Active |
| US9279794 | Systems and methods for compensating long term sensitivity drift of electrochemical gas sensors exposed to nitric oxide | 19 Aug, 2035 | Active |
| US9279794 | Systems and methods for compensating long term sensitivity drift of electrochemical gas sensors exposed to nitric oxide | 19 Feb, 2035 | Active |
| US8658631 | Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia | 16 May, 2032 | Active |
| US8741885 | Gastric retentive extended release pharmaceutical compositions | 16 May, 2032 | Active |
| US8992975 | Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia | 16 May, 2032 | Active |
| US9050335 | Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia | 16 May, 2032 | Active |
| US9468636 | Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia | 16 May, 2032 | Active |
| US9399012 | Reduced dose intravenous acetaminophen | 11 Mar, 2032 | Active |
| US9399012 | Reduced dose intravenous acetaminophen | 11 Sep, 2031 | Active |
| US8291904 | Gas delivery device and system | 06 Jul, 2031 | Active |
| US8573209 | Gas delivery device and system | 06 Jul, 2031 | Active |
| US8573210 | Nitric oxide delivery device | 06 Jul, 2031 | Active |
| US8776794 | Nitric oxide delivery device | 06 Jul, 2031 | Active |
| US8776795 | Gas delivery device and system | 06 Jul, 2031 | Active |
| US9265911 | Gas delivery device and system | 06 Jul, 2031 | Active |
| US9295802 | Gas delivery device and system | 06 Jul, 2031 | Active |
| US9408993 | Nitric oxide delivery device | 06 Jul, 2031 | Active |
| US8291904 | Gas delivery device and system | 06 Jan, 2031 | Active |
| US8573209 | Gas delivery device and system | 06 Jan, 2031 | Active |
| US8573210 | Nitric oxide delivery device | 06 Jan, 2031 | Active |
| US8776794 | Nitric oxide delivery device | 06 Jan, 2031 | Active |
| US8776795 | Gas delivery device and system | 06 Jan, 2031 | Active |
| US9265911 | Gas delivery device and system | 06 Jan, 2031 | Active |
| US9295802 | Gas delivery device and system | 06 Jan, 2031 | Active |
| US9408993 | Nitric oxide delivery device | 06 Jan, 2031 | Active |
| US8597681 | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans | 21 Dec, 2030 | Active |
| US8980319 | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans | 21 Dec, 2030 | Active |
| US11931377 | Methods of administering inhaled nitric oxide gas | 30 Dec, 2029 | Active |
| US8282966 | Methods of reducing the risk of occurrence of pulmonary edema in children in need of treatment with inhaled nitric oxide | 30 Dec, 2029 | Active |
| US8293284 | Methods of reducing the risk of occurrence of pulmonary edema in term or near-term neonates in need of treatment with inhaled nitric oxide | 30 Dec, 2029 | Active |
| US8431163 | Methods of reducing the risk of occurrence of pulmonary edema associated with inhalation of nitric oxide gas | 30 Dec, 2029 | Active |
| US8795741 | Methods for treating patients who are candidates for inhaled nitric oxide treatment | 30 Dec, 2029 | Active |
| US8846112 | Methods of distributing a pharmaceutical product comprising nitric oxide gas for inhalation | 30 Dec, 2029 | Active |
| US8377453 | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic | 19 Nov, 2029 | Active |
| US11931377 | Methods of administering inhaled nitric oxide gas | 30 Jun, 2029 | Active |
| US8282966 | Methods of reducing the risk of occurrence of pulmonary edema in children in need of treatment with inhaled nitric oxide | 30 Jun, 2029 | Active |
| US8293284 | Methods of reducing the risk of occurrence of pulmonary edema in term or near-term neonates in need of treatment with inhaled nitric oxide | 30 Jun, 2029 | Active |
| US8431163 | Methods of reducing the risk of occurrence of pulmonary edema associated with inhalation of nitric oxide gas | 30 Jun, 2029 | Active |
| US8795741 | Methods for treating patients who are candidates for inhaled nitric oxide treatment | 30 Jun, 2029 | Active |
| US8846112 | Methods of distributing a pharmaceutical product comprising nitric oxide gas for inhalation | 30 Jun, 2029 | Active |
| US10383834 | 13 May, 2029 | Active | |
| US9610265 | Reduced dose intravenous acetaminophen | 13 May, 2029 | Active |
| US9987238 | Reduced dose intravenous acetaminophen | 13 May, 2029 | Active |
| US8372432 | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic | 11 Mar, 2029 | Active |
| US8394408 | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic | 11 Mar, 2029 | Active |
| US8668929 | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic | 11 Mar, 2029 | Active |
| US10383834 | Reduced dose intravenous acetaminophen | 13 Nov, 2028 | Active |
| US9610265 | Reduced dose intravenous acetaminophen | 13 Nov, 2028 | Active |
| US9987238 | Reduced dose intravenous acetaminophen | 13 Nov, 2028 | Active |
| US7976870 | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract | 01 Jun, 2027 | Active |
| US6992218 | Method for obtaining aqueous formulations of oxidation-sensitive active principles | 06 Dec, 2021 | Expired |
| US6992218 | Method for obtaining aqueous formulations of oxidation-sensitive active principles | 06 Jun, 2021 | Expired |
| US6488962 | Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms | 20 Jun, 2020 | Expired |
| US6028222 | Stable liquid paracetamol compositions, and method for preparing same | 05 Feb, 2018 | Expired |
| US6125846 | Purge system for nitric oxide administration apparatus | 16 Nov, 2017 | Expired |
| US6028222 | Stable liquid paracetamol compositions, and method for preparing same | 05 Aug, 2017 | Expired |
| US5732693 | Pause control of nitric oxide therapy | 13 Jun, 2017 | Expired |
| US5752504 | System for monitoring therapy during calibration | 13 Jun, 2017 | Expired |
| US6125846 | Purge system for nitric oxide administration apparatus | 16 May, 2017 | Expired |
| US5732693 | Pause control of nitric oxide therapy | 13 Dec, 2016 | Expired |
| US5752504 | System for monitoring therapy during calibration | 13 Dec, 2016 | Expired |
| US5558083 | Nitric oxide delivery system | 22 May, 2014 | Expired |
| US5558083 | Nitric oxide delivery system | 22 Nov, 2013 | Expired |
| US5485827 | Methods and devices for treating plumonary vasoconstriction and asthma | 23 Jul, 2013 | Expired |
| US5873359 | Methods and devices for treating pulmonary vasoconstriction and asthma | 23 Jul, 2013 | Expired |
| US5485827 | Methods and devices for treating plumonary vasoconstriction and asthma | 23 Jan, 2013 | Expired |
| US5873359 | Methods and devices for treating pulmonary vasoconstriction and asthma | 23 Jan, 2013 | Expired |
Latest Legal Activities on Mallinckrodt's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Mallinckrodt.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 23 Apr, 2024 | US8291904 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 09 Feb, 2024 | US9408993 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 26 Jan, 2024 | US9399012 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 29 Sep, 2023 | US9295802 (Litigated) |
| Recordation of Patent eGrant | 12 Sep, 2023 | US11752199 |
|
Recordation of Patent Grant Mailed
Critical
| 12 Sep, 2023 | US11752199 |
| Sequence Moved to Public Database | 12 Sep, 2023 | US11752199 |
| Mail Patent eGrant Notification | 12 Sep, 2023 | US11752199 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 12 Sep, 2023 | US11752199 |
| Patent eGrant Notification | 12 Sep, 2023 | US11752199 |
|
Email Notification
Critical
| 12 Sep, 2023 | US11752199 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 08 Sep, 2023 | US9279794 (Litigated) |
|
Email Notification
Critical
| 24 Aug, 2023 | US11752199 |
|
Issue Notification Mailed
Critical
| 23 Aug, 2023 | US11752199 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 23 Aug, 2023 | US9265911 (Litigated) |
Mallinckrodt's Drug Patent Litigations
Mallinckrodt's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jan 05, 2015, against patent number US8795741. The petitioner Praxair Distribution, Inc., challenged the validity of this patent, with INO Therapeutics LLC as the respondent. Click below to track the latest information on how companies are challenging Mallinckrodt's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US8282966 | March, 2016 |
Institution Denied
(22 Sep, 2016)
| Mallinckrodt Hospital Products IP Ltd. et al. | Praxair Distribution, Inc. et al. |
| US8282966 | March, 2016 |
Terminated-Denied
(22 Sep, 2016)
| Mallinckrodt Hospital Products IP Ltd. | Praxair Distribution, Inc. |
| US8293284 | March, 2016 |
Institution Denied
(22 Sep, 2016)
| Mallinckrodt Hospital Products IP Ltd. et al. | Praxair Distribution, Inc. et al. |
| US8293284 | March, 2016 |
Terminated-Denied
(22 Sep, 2016)
| Mallinckrodt Hospital Products IP Ltd. | Praxair Distribution, Inc. |
| US8431163 | March, 2016 |
Institution Denied
(22 Sep, 2016)
| Mallinckrodt Hospital Products IP Ltd. et al. | Praxair Distribution, Inc. et al. |
| US8431163 | March, 2016 |
Terminated-Denied
(22 Sep, 2016)
| Mallinckrodt Hospital Products IP Ltd. | Praxair Distribution, Inc. |
| US8795741 | March, 2016 |
Institution Denied
(22 Sep, 2016)
| Mallinckrodt Hospital Products IP Ltd. et al. | Praxair Distribution, Inc. et al. |
| US8795741 | March, 2016 |
Terminated-Denied
(22 Sep, 2016)
| Mallinckrodt Hospital Products IP Ltd. | Praxair Distribution, Inc. |
| US8776795 | March, 2015 |
Final Written Decision
(19 Sep, 2016)
| INO Therapeutics LLC et al. | Praxair Distribution, Inc. et al. |
| US8776795 | March, 2015 |
FWD Entered
(19 Sep, 2016)
| INO Therapeutics LLC | Praxair Distribution, Inc. |
| US8573209 | March, 2015 |
Final Written Decision
(15 Sep, 2016)
| INO THERAPEUTICS LLC et al. | Praxair Distribution, Inc. et al. |
| US8573209 | March, 2015 |
FWD Entered
(15 Sep, 2016)
| INO THERAPEUTICS LLC | Praxair Distribution, Inc. |
| US8573210 | March, 2015 |
Final Written Decision
(15 Sep, 2016)
| INO Therapeutics LLC et al. | Praxair Distribution, Inc. et al. |
| US8573210 | March, 2015 |
FWD Entered
(15 Sep, 2016)
| INO Therapeutics LLC | Praxair Distribution, Inc. |
| US8776794 | March, 2015 |
Final Written Decision
(14 Sep, 2016)
| INO Therapeutics LLC et al. | Praxair Distribution, Inc. et al. |
| US8776794 | March, 2015 |
FWD Entered
(14 Sep, 2016)
| INO Therapeutics LLC | Praxair Distribution, Inc. |
| US8291904 | March, 2015 |
Final Written Decision
(12 Sep, 2016)
| INO Therapeutics LLC et al. | Praxair Distribution, Inc. et al. |
| US8291904 | March, 2015 |
FWD Entered
(12 Sep, 2016)
| INO Therapeutics LLC | Praxair Distribution, Inc. |
| US8846112 | March, 2016 |
Institution Denied
(25 Aug, 2016)
| Mallinckrodt Hospital Products IP Ltd. et al. | Praxair Distribution, Inc. et al. |
| US8846112 | March, 2016 |
Terminated-Denied
(25 Aug, 2016)
| Mallinckrodt Hospital Products IP Ltd. | Praxair Distribution, Inc. |
| US8846112 | January, 2015 |
Final Written Decision
(07 Jul, 2016)
| INO THERAPEUTICS LLC et al. | Praxair Distribution, Inc. et al. |
| US8846112 | January, 2015 |
FWD Entered
(07 Jul, 2016)
| INO THERAPEUTICS LLC | Praxair Distribution, Inc. |
| US8282966 | January, 2015 |
Institution Denied
(29 Jul, 2015)
| INO Therapeutics LLC et al. | Praxair Distribution, Inc. et al. |
| US8282966 | January, 2015 |
Terminated-Denied
(29 Jul, 2015)
| INO Therapeutics LLC | Praxair Distribution, Inc. |
| US8293284 | January, 2015 |
Institution Denied
(29 Jul, 2015)
| INO Therapeutics LLC et al. | Praxair Distribution, Inc. et al. |
| US8293284 | January, 2015 |
Terminated-Denied
(29 Jul, 2015)
| INO Therapeutics LLC | Praxair Distribution, Inc. |
| US8431163 | January, 2015 |
Institution Denied
(29 Jul, 2015)
| INO THERAPEUTICS LLC et al. | Praxair Distribution, Inc. et al. |
| US8431163 | January, 2015 |
Terminated-Denied
(29 Jul, 2015)
| INO THERAPEUTICS LLC | Praxair Distribution, Inc. |
| US8795741 | January, 2015 |
Institution Denied
(29 Jul, 2015)
| INO Therapeutics LLC et al. | Praxair Distribution, Inc. et al. |
| US8795741 | January, 2015 |
Terminated-Denied
(29 Jul, 2015)
| INO Therapeutics LLC | Praxair Distribution, Inc. |
Mallinckrodt's Family Patents
Mallinckrodt drugs have patent protection in a total of 19 countries. It's US patent count contributes only to 45.2% of its total global patent coverage. 3 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Mallinckrodt Drug List
Given below is the complete list of Mallinckrodt's drugs and the patents protecting them.
1. Acthar Gel
Acthar Gel is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11752199 | Methods of modulating pericytes |
18 Jul, 2041
(15 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Acthar Gel's drug page
2. Acthar Gel (autoinjector)
Acthar Gel (autoinjector) is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11752199 | Methods of modulating pericytes |
18 Jul, 2041
(15 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Acthar Gel (autoinjector)'s drug page
3. Inomax
Inomax is protected by 44 patents, out of which 12 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9770570
(Pediatric)
| Apparatus and method for monitoring nitric oxide delivery |
03 Nov, 2036
(10 years from now)
| Active |
| US9770570 | Apparatus and method for monitoring nitric oxide delivery |
03 May, 2036
(10 years from now)
| Active |
| US9279794
(Pediatric)
| Systems and methods for compensating long term sensitivity drift of electrochemical gas sensors exposed to nitric oxide |
19 Aug, 2035
(9 years from now)
| Active |
| US9279794 | Systems and methods for compensating long term sensitivity drift of electrochemical gas sensors exposed to nitric oxide |
19 Feb, 2035
(9 years from now)
| Active |
| US8291904
(Pediatric)
| Gas delivery device and system |
06 Jul, 2031
(5 years from now)
| Active |
| US8573209
(Pediatric)
| Gas delivery device and system |
06 Jul, 2031
(5 years from now)
| Active |
| US8573210
(Pediatric)
| Nitric oxide delivery device |
06 Jul, 2031
(5 years from now)
| Active |
| US8776794
(Pediatric)
| Nitric oxide delivery device |
06 Jul, 2031
(5 years from now)
| Active |
| US8776795
(Pediatric)
| Gas delivery device and system |
06 Jul, 2031
(5 years from now)
| Active |
| US9265911
(Pediatric)
| Gas delivery device and system |
06 Jul, 2031
(5 years from now)
| Active |
| US9295802
(Pediatric)
| Gas delivery device and system |
06 Jul, 2031
(5 years from now)
| Active |
| US9408993
(Pediatric)
| Nitric oxide delivery device |
06 Jul, 2031
(5 years from now)
| Active |
| US8291904 | Gas delivery device and system |
06 Jan, 2031
(4 years from now)
| Active |
| US8573209 | Gas delivery device and system |
06 Jan, 2031
(4 years from now)
| Active |
| US8573210 | Nitric oxide delivery device |
06 Jan, 2031
(4 years from now)
| Active |
| US8776794 | Nitric oxide delivery device |
06 Jan, 2031
(4 years from now)
| Active |
| US8776795 | Gas delivery device and system |
06 Jan, 2031
(4 years from now)
| Active |
| US9265911 | Gas delivery device and system |
06 Jan, 2031
(4 years from now)
| Active |
| US9295802 | Gas delivery device and system |
06 Jan, 2031
(4 years from now)
| Active |
| US9408993 | Nitric oxide delivery device |
06 Jan, 2031
(4 years from now)
| Active |
| US11931377
(Pediatric)
| Methods of administering inhaled nitric oxide gas |
30 Dec, 2029
(3 years from now)
| Active |
| US8282966
(Pediatric)
| Methods of reducing the risk of occurrence of pulmonary edema in children in need of treatment with inhaled nitric oxide |
30 Dec, 2029
(3 years from now)
| Active |
| US8293284
(Pediatric)
| Methods of reducing the risk of occurrence of pulmonary edema in term or near-term neonates in need of treatment with inhaled nitric oxide |
30 Dec, 2029
(3 years from now)
| Active |
| US8431163
(Pediatric)
| Methods of reducing the risk of occurrence of pulmonary edema associated with inhalation of nitric oxide gas |
30 Dec, 2029
(3 years from now)
| Active |
| US8795741
(Pediatric)
| Methods for treating patients who are candidates for inhaled nitric oxide treatment |
30 Dec, 2029
(3 years from now)
| Active |
| US8846112
(Pediatric)
| Methods of distributing a pharmaceutical product comprising nitric oxide gas for inhalation |
30 Dec, 2029
(3 years from now)
| Active |
| US11931377 | Methods of administering inhaled nitric oxide gas |
30 Jun, 2029
(3 years from now)
| Active |
| US8282966 | Methods of reducing the risk of occurrence of pulmonary edema in children in need of treatment with inhaled nitric oxide |
30 Jun, 2029
(3 years from now)
| Active |
| US8293284 | Methods of reducing the risk of occurrence of pulmonary edema in term or near-term neonates in need of treatment with inhaled nitric oxide |
30 Jun, 2029
(3 years from now)
| Active |
| US8431163 | Methods of reducing the risk of occurrence of pulmonary edema associated with inhalation of nitric oxide gas |
30 Jun, 2029
(3 years from now)
| Active |
| US8795741 | Methods for treating patients who are candidates for inhaled nitric oxide treatment |
30 Jun, 2029
(3 years from now)
| Active |
| US8846112 | Methods of distributing a pharmaceutical product comprising nitric oxide gas for inhalation |
30 Jun, 2029
(3 years from now)
| Active |
| US6125846
(Pediatric)
| Purge system for nitric oxide administration apparatus |
16 Nov, 2017
(8 years ago)
| Expired |
| US5732693
(Pediatric)
| Pause control of nitric oxide therapy |
13 Jun, 2017
(8 years ago)
| Expired |
| US5752504
(Pediatric)
| System for monitoring therapy during calibration |
13 Jun, 2017
(8 years ago)
| Expired |
| US6125846 | Purge system for nitric oxide administration apparatus |
16 May, 2017
(8 years ago)
| Expired |
| US5732693 | Pause control of nitric oxide therapy |
13 Dec, 2016
(9 years ago)
| Expired |
| US5752504 | System for monitoring therapy during calibration |
13 Dec, 2016
(9 years ago)
| Expired |
| US5558083
(Pediatric)
| Nitric oxide delivery system |
22 May, 2014
(11 years ago)
| Expired |
| US5558083 | Nitric oxide delivery system |
22 Nov, 2013
(12 years ago)
| Expired |
| US5485827
(Pediatric)
| Methods and devices for treating plumonary vasoconstriction and asthma |
23 Jul, 2013
(12 years ago)
| Expired |
| US5873359
(Pediatric)
| Methods and devices for treating pulmonary vasoconstriction and asthma |
23 Jul, 2013
(12 years ago)
| Expired |
| US5485827 | Methods and devices for treating plumonary vasoconstriction and asthma |
23 Jan, 2013
(12 years ago)
| Expired |
| US5873359 | Methods and devices for treating pulmonary vasoconstriction and asthma |
23 Jan, 2013
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Inomax's drug page
4. Ofirmev
Ofirmev is protected by 12 patents, out of which 4 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9399012
(Pediatric)
| Reduced dose intravenous acetaminophen |
11 Mar, 2032
(6 years from now)
| Active |
| US9399012 | Reduced dose intravenous acetaminophen |
11 Sep, 2031
(5 years from now)
| Active |
| US10383834
(Pediatric)
|
13 May, 2029
(3 years from now)
| Active | |
| US9610265
(Pediatric)
| Reduced dose intravenous acetaminophen |
13 May, 2029
(3 years from now)
| Active |
| US9987238
(Pediatric)
| Reduced dose intravenous acetaminophen |
13 May, 2029
(3 years from now)
| Active |
| US10383834 | Reduced dose intravenous acetaminophen |
13 Nov, 2028
(2 years from now)
| Active |
| US9610265 | Reduced dose intravenous acetaminophen |
13 Nov, 2028
(2 years from now)
| Active |
| US9987238 | Reduced dose intravenous acetaminophen |
13 Nov, 2028
(2 years from now)
| Active |
| US6992218
(Pediatric)
| Method for obtaining aqueous formulations of oxidation-sensitive active principles |
06 Dec, 2021
(4 years ago)
| Expired |
| US6992218 | Method for obtaining aqueous formulations of oxidation-sensitive active principles |
06 Jun, 2021
(4 years ago)
| Expired |
| US6028222
(Pediatric)
| Stable liquid paracetamol compositions, and method for preparing same |
05 Feb, 2018
(7 years ago)
| Expired |
| US6028222 | Stable liquid paracetamol compositions, and method for preparing same |
05 Aug, 2017
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ofirmev's drug page
5. Terlivaz
Terlivaz is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10335452 | Method of treating patients with hepatorenal syndrome type 1 |
05 Apr, 2037
(11 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Terlivaz's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List
6. Xartemis Xr
Xartemis Xr is protected by 13 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8658631 | Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia |
16 May, 2032
(6 years from now)
| Active |
| US8741885 | Gastric retentive extended release pharmaceutical compositions |
16 May, 2032
(6 years from now)
| Active |
| US8992975 | Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia |
16 May, 2032
(6 years from now)
| Active |
| US9050335 | Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia |
16 May, 2032
(6 years from now)
| Active |
| US9468636 | Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia |
16 May, 2032
(6 years from now)
| Active |
| US8597681 | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
21 Dec, 2030
(4 years from now)
| Active |
| US8980319 | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
21 Dec, 2030
(4 years from now)
| Active |
| US8377453 | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
19 Nov, 2029
(3 years from now)
| Active |
| US8372432 | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
11 Mar, 2029
(3 years from now)
| Active |
| US8394408 | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
11 Mar, 2029
(3 years from now)
| Active |
| US8668929 | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
11 Mar, 2029
(3 years from now)
| Active |
| US7976870 | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
01 Jun, 2027
(1 year, 4 months from now)
| Active |
| US6488962 | Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms |
20 Jun, 2020
(5 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xartemis Xr's drug page